Targeting FOSB with a cationic antimicrobial peptide, TP4, for treatment of triple-negative breast cancer.

Oncotarget · 2016 · PMC5130011 · PMID 27248170

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Grade I samples ( N = 6) showed a trend towards decrease, but were not statistically different to NAT (Figure 3A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.